Cargando…
Investigating Patients’ Preferences to Inform Drug Development Decisions: Novel Insights from a Discrete Choice Experiment in Migraine
There is limited evidence on the scope and overall benefit of patient-centred drug development decisions. The present study assessed patients’ preferences for the characteristics of an ideal migraine treatment through a discrete choice experiment in order to inform decision-making and drug developme...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124202/ https://www.ncbi.nlm.nih.gov/pubmed/34063035 http://dx.doi.org/10.3390/ijerph18094916 |
_version_ | 1783693133571162112 |
---|---|
author | Torbica, Aleksandra Rognoni, Carla Tarricone, Rosanna |
author_facet | Torbica, Aleksandra Rognoni, Carla Tarricone, Rosanna |
author_sort | Torbica, Aleksandra |
collection | PubMed |
description | There is limited evidence on the scope and overall benefit of patient-centred drug development decisions. The present study assessed patients’ preferences for the characteristics of an ideal migraine treatment through a discrete choice experiment in order to inform decision-making and drug development processes. We investigated the preferences according to five treatment attributes identified from a systematic literature review and two focus group elicitations. The heterogeneity of preferences was also investigated. Overall, the respondents considered the presence of adverse events, duration of treatment effect, reduction of symptom intensity, speed of effect and cost born by the patient as the most relevant treatment features. As expected, the patients preferred treatments with lower levels of adverse events and costs and treatments with greater speed, duration of treatment effect and effectiveness in reducing symptom intensity. There was significant preference heterogeneity only for the presence of adverse events. Compared to men, women had significantly higher preferences for quicker treatment effect and limited adverse events and reported higher preferences for costly treatments. The results of our survey help address research and development strategies in the pharmaceutical industry and public policy regarding treatments that are clinically effective and responsive to the needs expressed by patients. |
format | Online Article Text |
id | pubmed-8124202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81242022021-05-17 Investigating Patients’ Preferences to Inform Drug Development Decisions: Novel Insights from a Discrete Choice Experiment in Migraine Torbica, Aleksandra Rognoni, Carla Tarricone, Rosanna Int J Environ Res Public Health Article There is limited evidence on the scope and overall benefit of patient-centred drug development decisions. The present study assessed patients’ preferences for the characteristics of an ideal migraine treatment through a discrete choice experiment in order to inform decision-making and drug development processes. We investigated the preferences according to five treatment attributes identified from a systematic literature review and two focus group elicitations. The heterogeneity of preferences was also investigated. Overall, the respondents considered the presence of adverse events, duration of treatment effect, reduction of symptom intensity, speed of effect and cost born by the patient as the most relevant treatment features. As expected, the patients preferred treatments with lower levels of adverse events and costs and treatments with greater speed, duration of treatment effect and effectiveness in reducing symptom intensity. There was significant preference heterogeneity only for the presence of adverse events. Compared to men, women had significantly higher preferences for quicker treatment effect and limited adverse events and reported higher preferences for costly treatments. The results of our survey help address research and development strategies in the pharmaceutical industry and public policy regarding treatments that are clinically effective and responsive to the needs expressed by patients. MDPI 2021-05-05 /pmc/articles/PMC8124202/ /pubmed/34063035 http://dx.doi.org/10.3390/ijerph18094916 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Torbica, Aleksandra Rognoni, Carla Tarricone, Rosanna Investigating Patients’ Preferences to Inform Drug Development Decisions: Novel Insights from a Discrete Choice Experiment in Migraine |
title | Investigating Patients’ Preferences to Inform Drug Development Decisions: Novel Insights from a Discrete Choice Experiment in Migraine |
title_full | Investigating Patients’ Preferences to Inform Drug Development Decisions: Novel Insights from a Discrete Choice Experiment in Migraine |
title_fullStr | Investigating Patients’ Preferences to Inform Drug Development Decisions: Novel Insights from a Discrete Choice Experiment in Migraine |
title_full_unstemmed | Investigating Patients’ Preferences to Inform Drug Development Decisions: Novel Insights from a Discrete Choice Experiment in Migraine |
title_short | Investigating Patients’ Preferences to Inform Drug Development Decisions: Novel Insights from a Discrete Choice Experiment in Migraine |
title_sort | investigating patients’ preferences to inform drug development decisions: novel insights from a discrete choice experiment in migraine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124202/ https://www.ncbi.nlm.nih.gov/pubmed/34063035 http://dx.doi.org/10.3390/ijerph18094916 |
work_keys_str_mv | AT torbicaaleksandra investigatingpatientspreferencestoinformdrugdevelopmentdecisionsnovelinsightsfromadiscretechoiceexperimentinmigraine AT rognonicarla investigatingpatientspreferencestoinformdrugdevelopmentdecisionsnovelinsightsfromadiscretechoiceexperimentinmigraine AT tarriconerosanna investigatingpatientspreferencestoinformdrugdevelopmentdecisionsnovelinsightsfromadiscretechoiceexperimentinmigraine |